EMEA-001175-PIP01-11-M04 - paediatric investigation plan

Albiglutide

Key facts

• Invented name:
  • Eperzan
  • Eperzan
• Active Substance:
  Albiglutide
• Therapeutic area:
  Endocrinology-Gynaecology-Fertility-Metabolism
• Decision number:
  P/0272/2016
• PIP number:
  EMEA-001175-PIP01-11-M04
• Pharmaceutical form(s):
  Powder and solvent for solution for injection
• Condition(s) / indication(s):
  Treatment of type II diabetes mellitus
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  07/10/2016

Decision

P/0272/2016: EMA decision of 7 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for albiglutide (Eperzan), (EMEA-001175-PIP01-11-M04)

AdoptedReference Number: EMA/585484/2016